LLY-507: A Potent, Selective SMYD2 Inhibitor for Cancer and Fibrosis Research

Executive Summary: LLY-507 is a small molecule inhibitor targeting SMYD2, a lysine methyltransferase overexpressed in multiple cancers and implicated in renal fibrosis (Chen et al., 2023). It exhibits an IC50 <15 nM and >100-fold selectivity against non-SMYD2 methyltransferases (APExBIO). Cellular assays confirm submicromolar potency in blocking p53 Lys370 monomethylation without impacting global histone methylation. Preclinical studies show LLY-507 reduces cancer cell proliferation and fibrosis markers in vitro. No in vivo or clinical data are yet available, and the compound is recommended for research use only.

Biological Rationale

SMYD2 (SET and MYND domain-containing protein 2) is a protein-lysine methyltransferase. It monomethylates non-histone targets, notably p53 at Lys370, and histones H3K36 and H3K4 (Chen et al., 2023). Aberrant SMYD2 expression is observed in esophageal squamous cell carcinoma and is correlated with poor prognosis (APExBIO). SMYD2 activity also contributes to epithelial-mesenchymal transition (EMT), renal fibrosis, and inflammatory cytokine expression. Inhibition of SMYD2 disrupts these pathways, making it a strategic target in oncology and fibrosis research. Epigenetic regulation via lysine methylation is increasingly recognized as central to tumorigenesis and chronic kidney disease (Chen et al., 2023).

Mechanism of Action of LLY-507

LLY-507 is a highly selective, cell-active SMYD2 inhibitor. It binds competitively within the substrate peptide binding pocket of SMYD2. This binding blocks the enzyme's methyltransferase activity, specifically preventing monomethylation of lysine residues on protein substrates. In cellular models, LLY-507 robustly inhibits p53 Lys370 monomethylation at submicromolar concentrations (APExBIO). Notably, it does not significantly affect global histone methylation, reflecting SMYD2's cytoplasmic localization and substrate selectivity. The result is targeted modulation of methylation pathways associated with cancer cell survival and fibrogenesis.

Evidence & Benchmarks

• LLY-507 inhibits SMYD2 enzymatic activity with an IC50 < 15 nM in biochemical assays (APExBIO).
• Demonstrates >100-fold selectivity for SMYD2 over a panel of other methyltransferases and non-methyltransferase targets (APExBIO).
• Reduces p53 Lys370 monomethylation in cells at submicromolar concentrations (Chen et al., 2023).
• Does not significantly alter global histone methylation levels in cellular assays (APExBIO).
• Inhibits proliferation of liver, esophageal, and breast cancer cell lines in a dose-dependent manner (Chen et al., 2023).
• Suppresses EMT markers and fibrogenic proteins in models of renal fibrosis induced by cisplatin (Chen et al., 2023).
• No published in vivo or clinical trial data as of June 2024 (APExBIO).

Compared to LLY-507 and the Next Frontier in SMYD2 Inhibition, which explores future directions, this article provides a benchmark-driven, evidence-based perspective on current experimental results. For laboratory troubleshooting and assay design, see LLY-507 (SKU B6119): Scenario-Driven Solutions, which this article extends by supplying comparative selectivity and mechanistic evidence. For a broader mechanistic overview, refer to LLY-507: A Potent SMYD2 Inhibitor Transforming Cancer and Fibrosis Research, complemented here with updated data and product specifications.

Applications, Limits & Misconceptions

LLY-507 is designed for preclinical research targeting SMYD2-driven pathways. Its applications include:

• Cellular assays to investigate SMYD2's role in cancer, apoptosis, and fibrosis.
• Screening for compounds modulating the lysine methylation pathway.
• Quantitative studies of protein-lysine methyltransferase inhibition.

Common Pitfalls or Misconceptions

• LLY-507 is not validated for in vivo use: No pharmacokinetic or safety data are available for animal models.
• Not a pan-methyltransferase inhibitor: LLY-507 is highly selective for SMYD2 and does not broadly inhibit other methyltransferases.
• Limited solubility in aqueous buffers: The compound is insoluble in water and should be dissolved in DMSO or ethanol at >54 mg/mL for stock solutions (APExBIO).
• Not intended for clinical or diagnostic use: Research use only, per APExBIO and regulatory guidance.
• May not affect global histone methylation: Effects are specific to SMYD2 substrates, so broader chromatin changes may not be observed.

Workflow Integration & Parameters

LLY-507 (SKU B6119) from APExBIO is supplied as a solid with a molecular weight of 574.76 g/mol and chemical formula C36H42N6O. For cell-based assays, dissolve in DMSO (≥57.5 mg/mL) or ethanol (≥54.7 mg/mL). Store at -20°C to maintain stability. Recommended working concentrations are typically in the range of 0.1–5 μM for in vitro studies. The compound is optimal for apoptosis assays, cancer cell proliferation inhibition, and studies interrogating the lysine methylation pathway. For troubleshooting, see the scenario-driven guide at LLY-507: SMYD2 Inhibitor Solutions for Cancer & Fibrosis Research, which this article updates with the latest selectivity and substrate data.

Conclusion & Outlook

LLY-507 stands out as a potent, selective SMYD2 inhibitor for cell-active research in oncology and fibrosis. By specifically targeting lysine methylation on non-histone substrates, it enables precise dissection of SMYD2-driven pathways. While no in vivo or clinical data are yet available, LLY-507 remains a premier tool for apoptosis and cancer cell proliferation inhibition studies. For future directions, see LLY-507: Unlocking SMYD2 Inhibition for Precision Cancer Research, which is complemented here by up-to-date product benchmarks and research parameters. For full product details and ordering, visit LLY-507 at APExBIO.